| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total revenues | $6.96B+5.6% | $6.60B+2.7% | $6.42B+2.0% | $6.30B-64.2% | $17.59B |
| Gross profit | $8.25B+0.5% | $8.21B+3.6% | $7.92B+10.3% | $7.18B+0.1% | $7.17B |
| Selling, general, and administrative | $4.22B-1.0% | $4.27B-0.3% | $4.28B+17.9% | $3.63B+1.9% | $3.56B |
| Research and development | $1.26B-3.9% | $1.31B+8.8% | $1.21B+17.4% | $1.03B+25.7% | $816.0M |
| Total operating expenses | $5.49B-1.7% | $5.58B+1.7% | $5.49B+17.8% | $4.66B+6.3% | $4.38B |
| Operating income | $2.76B+5.3% | $2.63B+7.8% | $2.44B-3.4% | $2.52B-9.8% | $2.79B |
| Interest and other financial charges – net | $440.0M-12.7% | $504.0M-7.0% | $542.0M+603.9% | $77.0M+92.5% | $40.0M |
| Non-operating benefit (income) costs | -$288.0M+29.1% | -$406.0M-6.3% | -$382.0M-7540.0% | -$5.0M-266.7% | $3.0M |
| Other (income) expense – net | -$157.0M-185.5% | -$55.0M+36.0% | -$86.0M-38.7% | -$62.0M+49.6% | -$123.0M |
| Income from continuing operations before income taxes | $2.77B+7.2% | $2.58B+9.3% | $2.36B-6.0% | $2.51B-12.6% | $2.88B |
| Benefit (provision) for income taxes | -$614.0M-15.6% | -$531.0M+28.5% | -$743.0M-32.0% | -$563.0M+6.2% | -$600.0M |
| Net income from continuing operations | $2.15B+5.1% | $2.05B+26.7% | $1.62B-17.0% | $1.95B-14.3% | $2.27B |
| Income (loss) from discontinued operations, net of taxes | $0 | $0+100.0% | -$4.0M-122.2% | $18.0M+0.0% | $18.0M |
| Net income | $2.15B+5.1% | $2.05B+27.0% | $1.61B-17.9% | $1.97B-14.2% | $2.29B |
| Net (income) loss attributable to noncontrolling interests | -$70.0M-22.8% | -$57.0M-23.9% | -$46.0M+9.8% | -$51.0M-10.9% | -$46.0M |
| Net income attributable to GE HealthCare | $2.08B+4.6% | $1.99B+27.1% | $1.57B-18.2% | $1.92B-14.7% | $2.25B |
| Deemed preferred stock dividend of redeemable noncontrolling interest | $0 | $0+100.0% | -$183.0M | $0 | $0 |
| Net income attributable to GE HealthCare common stockholders | $2.08B+4.6% | $1.99B+43.9% | $1.39B-27.7% | $1.92B-14.7% | $2.25B |
| Basic (in dollars per share) | $4560000.00+4.3% | $4370000.00+43.3% | $3050000.00-27.7% | $4220000.00-14.7% | $4950000.00 |
| Diluted (in dollars per share) | $4550000.00+4.8% | $4340000.00+43.2% | $3030000.00-28.2% | $4220000.00-14.7% | $4950000.00 |
| Basic (in shares) | 456.0M+0.0% | 456.0M+0.2% | 455.0M+0.2% | 454.0M+0.0% | 454.0M |
| Diluted (in shares) | 458.0M-0.2% | 459.0M+0.2% | 458.0M+0.9% | 454.0M+0.0% | 454.0M |
| Product | |||||
| Cost of sales | $3.44B+7.5% | $3.20B+1.0% | $3.17B-0.7% | $3.19B-55.7% | $7.20B |
| Service | |||||
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Source: SEC EDGAR 10-K and 10-Q filings. Up to 10 years annual / 16 quarters shown.